Table 1 Summarized information for selected IC/CCs
From: Emergence and global spread of a dominant multidrug-resistant clade within Acinetobacter baumannii
International Clone (IC) | IC1(CC1) | IC2(CC2) | ESL | Other ICs | Non-ICs | All |
|---|---|---|---|---|---|---|
Number of Isolates | 1094 | 9726 | 10,820 | 1492 | 3331 | 15,643 |
Years of isolation | ||||||
Before 2000 | 21 | 16 | 37 | 12 | 57 | 106 |
2001–2010 | 265 | 912 | 1177 | 295 | 463 | 1935 |
2011–2020 | 462 | 4739 | 5201 | 680 | 1415 | 7296 |
2021– | 46 | 1831 | 1877 | 75 | 493 | 2445 |
ARGs | ||||||
Non OXA-51 family Carbapenemase | 81.9% | 83.6% | 83.4% | 69.5% | 35.8% | 72.0% |
Minocycline | 18.7% | 72.4% | 67.0% | 23.2% | 8.0% | 50.2% |
Sulbactam | 17.2% | 93.6% | 85.9% | 20.9% | 5.4% | 62.5% |
Quinolone | 97.2% | 99.7% | 99.4% | 91.0% | 47.9% | 87.7% |
Macrolide | 27.2% | 69.0% | 64.8% | 34.3% | 17.6% | 51.8% |
Sulfonamide | 90.0% | 79.3% | 81.3% | 79.8% | 57.0% | 75.4% |
Fosfomycin | 92.5% | 98.2% | 97.6% | 97.4% | 81.5% | 94.1% |
Aminoglycoside | 100.00% | 100.00% | 100% | 100.00% | 93.6% | 98.6% |
num ARGs | 15.3 | 17.1 | 16.9 | 14.6 | 9.1 | 15.1 |
num AMR types | 6.5 | 6.5 | 6.5 | 6.1 | 4.4 | 6.1 |
